403
Sorry!!
Error! We're sorry, but the page you were looking for doesn't exist.
Takeda's President Of Growth And Emerging Markets Advances Strategic Partnerships With Saudi Health Leaders
(MENAFN- Mid-East Info) Gamze Yüceland advances dialogue with Saudi healthcare leaders to accelerate sector transformation and align with Vision 2030 goals
Riyadh, Kingdom of Saudi Arabia, November 4, 2025: Demonstrating Takeda's active support for Saudi Arabia's Vision 2030, Gamze Yüceland, President of Growth and Emerging Markets, visited the Kingdom to meet with prominent healthcare stakeholders. The meetings with leaders from the Saudi Food and Drug Authority (SFDA), King Faisal Specialist Hospital & Research Centre (KFSHRC), King Saud University Sleep Center, and King Saud University Medical City (KSUMC) focused on strengthening partnerships to drive medical innovation, expand access to specialized care, and boost research and education. “Takeda is proud to help advance high-quality, digital, and sustainable patient-cantered care in line with Saudi Arabia's Vision 2030 objectives,” said Gamze Yüceland. “By building strategic collaborations, we aim to enrich medical education, foster research innovation, and boost awareness across key therapeutic areas such as oncology, hematology, gastroenterology, and neuroscience, helping ensure world-class care for patients throughout the Kingdom.” Khaled Sary, Takeda West Gulf Cluster General Manager, added, “This visit further solidifies the trust and strong partnerships Takeda has built within the Kingdom, confirming our enduring commitment to the Vision 2030 health sector transformation through impactful collaboration.” Central to Takeda's strategy in emerging markets is a steadfast commitment to collaborating with local partners in support of national priorities. During a recent meeting with the Saudi Food and Drug Authority (SFDA), discussions focused on initiatives to strengthen regulatory frameworks and advance clinical trial enablement. The engagement also provided an opportunity to recognize the Authority's significant achievements and to explore avenues for future collaboration. Ms. Yüceland also engaged with leaders at the King Faisal Specialist Hospital Research Centre (KFSHRC), recognized for its excellence in oncology, hematology, and transplantation. The discussions cantered on KFSHRC's ongoing transformation into a premier centre of excellence in specialized care, research, and innovation. Both parties explored how Takeda's global expertise could further advance this vision through collaborative initiatives spanning key therapeutic areas. At the King Saud University Sleep Center, the dialogue underscored Saudi Arabia's growing leadership in sleep research and disorder management. The conversations highlighted the Kingdom's potential to emerge as a regional hub for pioneering therapies, further strengthening its role in advancing global sleep science. During her visit to King Saud University Medical City (KSUMC), Ms. Yüceland highlighted Takeda's commitment to elevating patient care and driving progress in gastroenterology research. Building on two previously signed Memorandum of Understanding in 2022 and 2025, the discussions focused on expanding clinical training, enhancing research capabilities, and improving health outcomes across the Kingdom. Gamze Yüceland's recent engagements highlight Takeda's integral role in Saudi Arabia's healthcare transformation, demonstrating the company's ongoing commitment to advancing research, partnership, and high-quality patient care in alignment with Vision 2030. *** About Takeda Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit .
Riyadh, Kingdom of Saudi Arabia, November 4, 2025: Demonstrating Takeda's active support for Saudi Arabia's Vision 2030, Gamze Yüceland, President of Growth and Emerging Markets, visited the Kingdom to meet with prominent healthcare stakeholders. The meetings with leaders from the Saudi Food and Drug Authority (SFDA), King Faisal Specialist Hospital & Research Centre (KFSHRC), King Saud University Sleep Center, and King Saud University Medical City (KSUMC) focused on strengthening partnerships to drive medical innovation, expand access to specialized care, and boost research and education. “Takeda is proud to help advance high-quality, digital, and sustainable patient-cantered care in line with Saudi Arabia's Vision 2030 objectives,” said Gamze Yüceland. “By building strategic collaborations, we aim to enrich medical education, foster research innovation, and boost awareness across key therapeutic areas such as oncology, hematology, gastroenterology, and neuroscience, helping ensure world-class care for patients throughout the Kingdom.” Khaled Sary, Takeda West Gulf Cluster General Manager, added, “This visit further solidifies the trust and strong partnerships Takeda has built within the Kingdom, confirming our enduring commitment to the Vision 2030 health sector transformation through impactful collaboration.” Central to Takeda's strategy in emerging markets is a steadfast commitment to collaborating with local partners in support of national priorities. During a recent meeting with the Saudi Food and Drug Authority (SFDA), discussions focused on initiatives to strengthen regulatory frameworks and advance clinical trial enablement. The engagement also provided an opportunity to recognize the Authority's significant achievements and to explore avenues for future collaboration. Ms. Yüceland also engaged with leaders at the King Faisal Specialist Hospital Research Centre (KFSHRC), recognized for its excellence in oncology, hematology, and transplantation. The discussions cantered on KFSHRC's ongoing transformation into a premier centre of excellence in specialized care, research, and innovation. Both parties explored how Takeda's global expertise could further advance this vision through collaborative initiatives spanning key therapeutic areas. At the King Saud University Sleep Center, the dialogue underscored Saudi Arabia's growing leadership in sleep research and disorder management. The conversations highlighted the Kingdom's potential to emerge as a regional hub for pioneering therapies, further strengthening its role in advancing global sleep science. During her visit to King Saud University Medical City (KSUMC), Ms. Yüceland highlighted Takeda's commitment to elevating patient care and driving progress in gastroenterology research. Building on two previously signed Memorandum of Understanding in 2022 and 2025, the discussions focused on expanding clinical training, enhancing research capabilities, and improving health outcomes across the Kingdom. Gamze Yüceland's recent engagements highlight Takeda's integral role in Saudi Arabia's healthcare transformation, demonstrating the company's ongoing commitment to advancing research, partnership, and high-quality patient care in alignment with Vision 2030. *** About Takeda Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit .
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research
More Story
Comments
No comment